novavax
commonwealth
australia
announce
agreement
principle
acquisition
novavax
vaccine
gaithersburg
globe
newswire
novavax
nasdaq
nvax
late
stage
biotechnology
company
developing
vaccines
serious
infectious
diseases
today
announced
signing
heads
terms
document
australian
government
supply
million
doses
company
vaccine
candidate
australian
community
arrangement
australian
government
reflects
importance
ongoing
clinical
development
ensure
citizens
australia
access
supply
said
stanley
erck
president
chief
executive
officer
novavax
pleased
progress
ongoing
phase
clinical
trial
uk
pressing
forward
deliver
efficacy
data
interim
data
trial
expected
soon
early
first
quarter
heads
terms
provides
delivery
australia
starting
early
first
half
subject
successful
completion
phase
clinical
development
approval
vaccine
australia
therapeutic
goods
administration
tga
vaccine
regimen
expected
require
two
doses
per
individual
administered
days
apart
date
novavax
established
various
agreements
supply
directly
united
states
united
kingdom
canada
australia
partnerships
supply
japan
south
korea
india
australia
clinical
trial
contribution
australia
played
pivotal
role
clinical
development
program
australian
clinical
researchers
led
global
phase
clinical
trial
august
trial
involved
australians
across
two
trial
sites
melbourne
brisbane
addition
approximately
australians
participated
phase
arm
clinical
trial
conducted
across
sites
australia
planned
global
phase
clinical
programs
evaluating
assess
immunity
safety
disease
prevention
trials
seek
recruit
members
community
vulnerable
elderly
underlying
medical
conditions
well
diverse
racial
ethnic
representation
vaccine
candidate
engineered
genetic
sequence
virus
causes
disease
created
using
novavax
recombinant
nanoparticle
technology
generate
antigen
derived
coronavirus
spike
protein
contains
novavax
patented
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
contains
purified
protein
antigen
replicate
cause
preclinical
trials
demonstrated
induction
antibodies
block
binding
spike
protein
receptors
targeted
virus
critical
aspect
effective
vaccine
protection
phase
portion
phase
clinical
trial
generally
elicited
robust
antibody
responses
numerically
superior
seen
human
convalescent
sera
also
evaluated
phase
trial
uk
two
ongoing
phase
studies
began
august
phase
trial
south
africa
phase
continuation
australia
novavax
secured
billion
funding
global
coronavirus
vaccine
program
including
million
funding
coalition
epidemic
preparedness
innovations
cepi
novavax
patented
adjuvant
demonstrated
potent
effect
stimulating
entry
antigen
presenting
cells
injection
site
enhancing
antigen
presentation
local
lymph
nodes
boosting
immune
response
manufacturing
novavax
progressing
manufacturing
across
multiple
locations
around
world
delivery
initial
doses
vaccine
expected
early
end
year
goal
expand
production
enable
delivery
billion
doses
annually
production
online
novavax
novavax
nasdaq
nvax
biotechnology
company
promotes
improved
health
globally
discovery
development
commercialization
innovative
vaccines
prevent
serious
infectious
diseases
novavax
currently
conducting
multiple
clinical
trials
vaccine
candidate
virus
causes
including
pivotal
phase
clinical
trial
united
kingdom
evaluate
efficacy
safety
immunogenicity
individuals
aged
years
age
quadrivalent
influenza
nanoparticle
vaccine
met
primary
objectives
pivotal
phase
clinical
trial
older
adults
candidate
vaccines
incorporate
novavax
proprietary
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
novavax
leading
innovator
recombinant
vaccines
proprietary
recombinant
technology
platform
combines
power
speed
genetic
engineering
efficiently
produce
highly
immunogenic
nanoparticles
order
address
urgent
global
health
needs
information
visit
connect
us
twitter
linkedin
novavax
statements
statements
herein
relating
future
novavax
ongoing
development
vaccine
adjuvant
products
statements
novavax
cautions
statements
subject
numerous
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
implied
statements
risks
uncertainties
include
identified
heading
risk
factors
novavax
annual
report
form
year
ended
december
quarterly
report
form
period
ended
june
filed
securities
exchange
commission
sec
caution
investors
place
considerable
reliance
statements
contained
press
release
encouraged
read
filings
sec
available
discussion
risks
uncertainties
statements
press
release
speak
date
document
undertake
obligation
update
revise
statements
business
subject
substantial
risks
uncertainties
including
referenced
investors
potential
investors
others
give
careful
consideration
risks
uncertainties
additional
contacts
novavax
investors
erika
trahan
ir
international
media
edna
kaplan
kaplan
novavax
outside
australia
australia
sparrow
cameron
